Molecular cross-talk between the TRAIL and interferon signaling pathways

Area of Science:

• Molecular Biology
• Cancer Research
• Immunology

Background:

• TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand) induces apoptosis in cancer cells, showing therapeutic potential.
• The full scope of TRAIL-mediated signaling extends beyond simple caspase activation.
• Understanding TRAIL's complex signaling is crucial for developing effective anti-cancer therapies.

Purpose of the Study:

• To investigate TRAIL-mediated gene expression in breast carcinoma cells using DNA microarrays.
• To elucidate the molecular interactions between TRAIL and interferon signaling pathways.
• To explore the combined therapeutic potential of TRAIL and interferon-beta in breast cancer.

Main Methods:

• DNA microarrays were employed to profile gene expression changes induced by TRAIL in breast cancer cells.
• Analysis focused on identifying primary response genes and interferon-related signaling pathways.
• In vitro experiments combined TRAIL and interferon-beta to assess synergistic effects on apoptosis and caspase activation.

Main Results:

• TRAIL induced known NF-kappaB-dependent genes (e.g., cIAP2, A20, E-selectin) and a significant cohort of interferon-signaling pathway genes.
• Evidence of molecular cross-talk was observed, including interferon-mediated upregulation of TRAIL and TRAIL-mediated induction of interferon-beta.
• Combined treatment with TRAIL and interferon-beta synergistically enhanced apoptosis and caspase activation in breast cancer cells.

Conclusions:

• TRAIL signaling in breast cancer cells involves intricate cross-talk with the interferon pathway.
• The combination of TRAIL and interferon-beta demonstrates synergistic anti-tumor activity.
• These findings highlight novel therapeutic strategies by combining TRAIL and interferon-based treatments for breast cancer.